BioXcel Therapeutics, Inc. (BTAI)

2.5650 -0.0050 (-0.19%) As of 01:26PM EDT. Market open.

BioXcel Therapeutics, Inc.

555 Long Wharf Drive
12th Floor
New Haven, CT 06511
United States
475 238 6837
https://www.bioxceltherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 74

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Vimal D. Mehta Ph.D.	Founder, CEO, President, & Director	1.02M	N/A	1962
Mr. Javier Rodriguez	Senior VP, Chief Legal Officer & Corporate Secretary	432.08k	N/A	1973
Mr. Matthew Wiley	Senior VP & Chief Commercial Officer	453.45k	N/A	1973
Mr. Richard I. Steinhart MBA	Senior VP & CFO	404k	N/A	1957
Dr. Frank D. Yocca Ph.D.	Senior VP & Chief Scientific Officer	452.58k	N/A	1957
Dr. Vincent J. O'Neill B.Sc., M.D., M.R.C.P.	Executive VP and Chief of Product Development & Medical Officer	510.17k	N/A	1969
Dr. Chetan D. Lathia Ph.D.	Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs	N/A	N/A	N/A
Dr. Robert Risinger M.D.	Chief Medical Officer - Neuroscience	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Corporate governance

BioXcel Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.